Compare Automatic Data Processing Inc (ADP) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Amgen, Inc. — how do they compare? Automatic Data Processing Inc trades at $271.34 (market cap $107.69B), while Amgen, Inc. trades at $416.99 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 2.1× Automatic Data Processing Inc's market cap, and Automatic Data Processing Inc pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| ADP | AMGN | |
|---|---|---|
Market Cap | $107.69B | $224.14B |
Sector | Industrials | Health |
52-Week High | $309.03 | $417.20 |
52-Week Low | $188.79 | $271.18 |
Enterprise Value | $108.73B | $267.45B |
Dividend Yield | 2.51% | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $269.14, down 1.66% on the day, with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings, beating estimates with EPS of $2.62 versus $2.57 expected, and revenue growth continues steadily. Analyst consensus is a $280.50 price target, though the majority rating is Hold. Recent news highlights dividend declarations and employment data reports.
Outlook remains positive due to consistent earnings beats and margin expansion, but high valuation multiples like a P/E of 24.78 pose a risk if growth slows. Key risks include economic sensitivity affecting payroll services demand and competitive pressures in HR solutions.
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
